Is Abivax S.A. (ABVX) a Buy, Sell, or Hold?
Abivax S.A.
NASDAQ:ABVX
$134.91 USD
-$1.07 (-0.79%)
- Volume
- 933.13K
- Average Volume
- 2.06M
- Market Capitalization
- $9.91B
- P/E Ratio
- -24.55
- Dividend Yield
- 0.00%
- Price Target
- $155.00
- Year High
- $148.83
- Year Low
- $8.85
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.75
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Marc de Garidel |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ABVX |
| CUSIP | 00370M103 |
| CIK | 0001956827 |
| Web | https://www.abivax.com |
| Phone | 33 1 53 83 08 41 |
| Currency | USD |
| Employees | 80 |
| Country | FR |
Liquidity
| Debt-to-Equity Ratio | 0.10 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.75 |
| Quick Ratio | 8.75 |
| Cash Ratio | 8.20 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.33 |
| Price / Cash Flow | -53.68 |
| Price / Book | 18.11 |
Price Target and Rating
| Average Stock Price Forecast | $155.00 |
| High Stock Price Forecast | $175.00 |
| Low Stock Price Forecast | $90.00 |
| Forecast Upside/Downside | -12.96% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 13 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.65 |
| Trailing P/E Ratio | -24.55 |
| PEG Ratio | 0.40 |
| P/E Growth | 0.40 |
| Net Income | $-336.1M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -165.19% |
| Return on Assets | -57.52% |
Financials Score
| AltmanZ Score | 35.81 |
| Piotroski Score | 3.00 |
| Working Capital | 540.53M |
| Total Assets | 652.05M |
| Ebit | -384.55M |
| Market Cap | 9B |
| Total Liabilities | 140.81M |
Poll Results
About Abivax S.A. (NASDAQ:ABVX) Stock
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncy ... tial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?
2026-07-10 10:56:06
After reaching an important support level, Abivax SA Sponsored ADR (ABVX) could be a good stock pick from a technical perspective. ABVX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
2026-07-10 06:10:15
Abivax's latest funding round allows the biotech to move toward a U.S. launch of its bowel disease drug without backing from Big Pharma, its CEO told CNBC on Friday. The French biotech has been under intense scrutiny as an acquisition target by a larger peer.
3 Soaring Stocks That May Have More Upside Ahead
2026-07-07 19:15:00
The sky is the limit for these companies.
Abivax: Wall Street Catches Up to the Data
2026-07-07 12:25:55
Shares of Abivax NASDAQ: ABVX were up more than 40% in the month ending July 6, after the company announced positive results from its late-stage (Phase 3) trial of its lead candidate, Obefazimod, which is being designed as a long-term maintenance treatment for ulcerative colitis (UC). The rally pushed ABVX nearly to its all-time high of $146.41, set in December 2025.
Abivax Announces Closing of $920 Million Public Offering
2026-07-06 16:05:00
Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 7,360,000 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.01 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “Offering”), which includes the full exercise of the underwriters' option to purchase additional ADSs (the “Underwriters' Option”).
Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet
2026-07-02 05:25:00
Shares rose 5% after the biotech moved to bolster its balance sheet through an upsized stock offering, signaling investor appetite in the wake of positive clinical-trial data.
2026-07-02 02:00:00
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax nears $11 billion valuation after fundraising eases M&A pressure
2026-07-01 19:02:42
Abivax SA raised $800 million in an expanded share sale on Wednesday after strong investor demand, valuing the French biotechnology company at nearly $11 billion and easing pressure to pursue a near-term sale.
Frequently Asked Questions
-
What is the current Abivax S.A. (ABVX) stock price?
-
Abivax S.A.(NASDAQ:ABVX) stock price is $134.91 in the last trading session. During the trading session, ABVX stock reached the peak price of $148.83 while $8.848 was the lowest point it dropped to. The percentage change in ABVX stock occurred in the recent session was --0.79% while the dollar amount for the price change in ABVX stock was -$-1.07.
-
ABVX's industry and sector of operation?
-
The NASDAQ listed ABVX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ABVX?
-
Patrick Malloy | Senior VP & Head of Investor Relations
Chris Rabbat | Vice President & Global Head of Medical Affairs
Hema Keshava | Senior Vice President of Finance
Kevin Shan | Vice President & Global Head of Biometrics
Mary Mantock | Senior VP & Global Head of Regulatory Affairs -
How many employees does ABVX have?
-
Number of ABVX employees currently stands at 80. ABVX operates from 5, rue de la Baume, Paris, IF 75008, FR.
-
Link for ABVX official website?
-
Official Website of ABVX is: https://www.abivax.com
-
How do I contact ABVX?
-
ABVX could be contacted at phone #33 1 53 83 08 41 and can also be accessed through its website. ABVX operates from 5, rue de la Baume, Paris, IF 75008, FR.
-
How many shares of ABVX are traded daily?
-
The average number of ABVX shares traded daily for last 3 months was 2.06M.
-
What is the market cap of ABVX currently?
-
The market value of ABVX currently stands at $9.91B with its latest stock price at $134.91